| pubmed-article:20951584 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20951584 | lifeskim:mentions | umls-concept:C0034428 | lld:lifeskim |
| pubmed-article:20951584 | lifeskim:mentions | umls-concept:C0162758 | lld:lifeskim |
| pubmed-article:20951584 | lifeskim:mentions | umls-concept:C0753726 | lld:lifeskim |
| pubmed-article:20951584 | lifeskim:mentions | umls-concept:C0243076 | lld:lifeskim |
| pubmed-article:20951584 | pubmed:issue | 23 | lld:pubmed |
| pubmed-article:20951584 | pubmed:dateCreated | 2010-11-8 | lld:pubmed |
| pubmed-article:20951584 | pubmed:abstractText | 5-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2(1H)-quinolinones and 3,4-dihydro-2(1H)-quinolinones have been identified with different combinations of 5-HT(1) autoreceptor antagonist and hSerT potencies and excellent rat PK profiles. The availability of tool compounds with a range of profiles at targets known to play a key role in the control of synaptic 5-HT levels will allow exploration of different pharmacological profiles in a range of animal behavioral and disease models. | lld:pubmed |
| pubmed-article:20951584 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20951584 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20951584 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20951584 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20951584 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20951584 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20951584 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20951584 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20951584 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:20951584 | pubmed:issn | 1464-3405 | lld:pubmed |
| pubmed-article:20951584 | pubmed:author | pubmed-author:ArbanRobertoR | lld:pubmed |
| pubmed-article:20951584 | pubmed:author | pubmed-author:BromidgeSteve... | lld:pubmed |
| pubmed-article:20951584 | pubmed:author | pubmed-author:WorbyAngelaA | lld:pubmed |
| pubmed-article:20951584 | pubmed:author | pubmed-author:ZonziniLauraL | lld:pubmed |
| pubmed-article:20951584 | pubmed:author | pubmed-author:BertaniBarbar... | lld:pubmed |
| pubmed-article:20951584 | pubmed:author | pubmed-author:PasquarelloAl... | lld:pubmed |
| pubmed-article:20951584 | pubmed:author | pubmed-author:FaedoStefania... | lld:pubmed |
| pubmed-article:20951584 | pubmed:author | pubmed-author:GordonLaurie... | lld:pubmed |
| pubmed-article:20951584 | pubmed:author | pubmed-author:BorrielloManu... | lld:pubmed |
| pubmed-article:20951584 | pubmed:author | pubmed-author:CapelliAnna-M... | lld:pubmed |
| pubmed-article:20951584 | pubmed:author | pubmed-author:GranciEnricaE | lld:pubmed |
| pubmed-article:20951584 | pubmed:author | pubmed-author:ZucchelliVale... | lld:pubmed |
| pubmed-article:20951584 | pubmed:author | pubmed-author:GianottiMassi... | lld:pubmed |
| pubmed-article:20951584 | pubmed:author | pubmed-author:Di-FabioRoman... | lld:pubmed |
| pubmed-article:20951584 | pubmed:author | pubmed-author:SpadaSimone... | lld:pubmed |
| pubmed-article:20951584 | pubmed:copyrightInfo | Copyright © 2010 Elsevier Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:20951584 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20951584 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:20951584 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:20951584 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20951584 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20951584 | pubmed:pagination | 7092-6 | lld:pubmed |
| pubmed-article:20951584 | pubmed:meshHeading | pubmed-meshheading:20951584... | lld:pubmed |
| pubmed-article:20951584 | pubmed:meshHeading | pubmed-meshheading:20951584... | lld:pubmed |
| pubmed-article:20951584 | pubmed:meshHeading | pubmed-meshheading:20951584... | lld:pubmed |
| pubmed-article:20951584 | pubmed:meshHeading | pubmed-meshheading:20951584... | lld:pubmed |
| pubmed-article:20951584 | pubmed:meshHeading | pubmed-meshheading:20951584... | lld:pubmed |
| pubmed-article:20951584 | pubmed:meshHeading | pubmed-meshheading:20951584... | lld:pubmed |
| pubmed-article:20951584 | pubmed:meshHeading | pubmed-meshheading:20951584... | lld:pubmed |
| pubmed-article:20951584 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20951584 | pubmed:articleTitle | 5-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2(1H)-quinolinones and 3,4-dihydro-2(1H)-quinolinones: dual-acting 5-HT1 receptor antagonists and serotonin reuptake inhibitors. Part 3. | lld:pubmed |
| pubmed-article:20951584 | pubmed:affiliation | Neurosciences CEDD, GlaxoSmithKline, New Frontiers Science Park, Harlow, Essex, UK. steven.bromidge@evotec.com | lld:pubmed |
| pubmed-article:20951584 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:20951584 | lld:chembl |
